Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 8, 2025

Primary Completion Date

July 8, 2026

Study Completion Date

July 8, 2027

Conditions

ITP - Immune Thrombocytopenia

Interventions

DRUG

Avatrombopag 20 mg Oral Tablet

Description: Patients will start on avatrombopag 20 mg every other day for a week then the dose will be readjusted according to the platelet count.

Trial Locations (1)

RECRUITING

hematology center / Medical City, Baghdad

All Listed Sponsors

lead

Al-Mustansiriyah University

OTHER